Reduction of ventricular arrhythmias by phosphocreatine (Neoton) in patients with acute myocardial infarction

Ruda, Mikhail; Samarenko, M. B.; Afonskaya, N. I.; Saks, Valdur

doi:10.1016/0002-8703(88)90611-4

Cited by 43 publications

(25 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ventricular fibrillation occurred in two control patients and in no PCr‐treated patient. The number of ventricular tachycardia episodes and the number of ventricular complexes occurring in paroxysms of ventricular tachycardia were significantly higher in control than in PCr‐treated patients . It is known that while ventricular arrhythmias occurring in the subacute phase of MI are often associated with signs and symptoms of heart failure, the incidence of early arrhythmias does not reflect the severity of pump dysfunction .…”

Section: Clinical Use Of Creatine or Its Derivativesmentioning

confidence: 93%

Therapeutic Use of Creatine in Brain or Heart Ischemia: Available Data and Future Perspectives

Perasso

Spallarossa

Ruggeri

et al. 2011

Medicinal Research Reviews

View full text Add to dashboard Cite

Creatine (Cr) is essential in safeguarding ATP levels and in moving ATP from its production site (mitochondria) to the cytoplasmic regions where it is used. Moreover, it has effects unrelated to energy metabolism, such as free radical scavenging, antiapoptotic action, and protection against excitotoxicity. Recent research has studied Cr-derived compounds (Cr benzyl ester and phos-pho-Cr-magnesium complex) that reproduce the neuroprotective effects of Cr while better crossing the neuronal plasma membrane and, hopefully, the blood-brain barrier (BBB). Intracellular levels of Cr can be increased by incubation with Cr or some of its derivatives, and this increase is protective against anoxic or ischemic damage. A large amount of experimental evidence shows that pretreatment with Cr is capable of reducing the damage induced by ischemia or anoxia in both heart and brain, and that such treatment may also be useful even after stroke or myocardial infarction (MI) has already occurred. Cr has been safely administered to patients affected by several neurological diseases, yet it has never been tested in human brain ischemia, the condition where its rationale is strongest. Phosphocreatine (PCr) has been administered after human MI, where it proved to be safe and probably helpful. Cr should be tested in the prophylactic protection against human brain ischemia and either Cr or PCr should be further tested in MI. Moreover, Cr- or PCr-derived drugs should be developed in order to overcome these molecules' limitations in crossing the BBB and the cell plasma membrane.

show abstract

Section: Clinical Use Of Creatine or Its Derivativesmentioning

confidence: 93%

Therapeutic Use of Creatine in Brain or Heart Ischemia: Available Data and Future Perspectives

Perasso

Spallarossa

Ruggeri

et al. 2011

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…However, since creatine would have to be energetically charged to PCr before it could develop its potential, and because the tissue in question is itself energy-depleted and thus cannot use its ATP to charge PCr, creatine should then be administered preventively to patients at high risk of stroke, even before the event takes place. An alternative approach, proposed and researched successfully by the group around Valdur Saks already in the 1980s (Ruda et al 1988) and followed up by Balestrino et al (2016), is that PCr is directly administered to patients by intravenous infusion as early as possible after an ischemic heart attack and during cardiac surgery. This strategy resulted in a significant improvement in cardiac parameters and subsequent prevention of cardiac arrhythmia, which is often also a problem after cardiac surgery.…”

Section: Creatine In Heart Function and Liver Pathologymentioning

confidence: 99%

Creatine: a miserable life without it

Wallimann

Harris

2016

Amino Acids

View full text Add to dashboard Cite

“…Phosphocreatine (PCr) promoted recovery of ischemic heart tissue in vitro and reduced arhythmias in patients with acute myocardial infarctions (Sharov et al . 1987; Ruda et al . 1988).…”

mentioning

confidence: 99%

On the mechanisms of neuroprotection by creatine and phosphocreatine

Brustovetsky¹,

Brustovetsky²,

Dubinsky³

2001

Journal of Neurochemistry

118

View full text Add to dashboard Cite

Creatine and phosphocreatine were evaluated for their ability to prevent death of cultured striatal and hippocampal neurons exposed to either glutamate or 3-nitropropionic acid (3NP) and to inhibit the mitochondrial permeability transition in CNS mitochondria. Phosphocreatine (PCr), and to a lesser extent creatine (Cr), but not (5R,10S)-(1)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate (MK801), dose-dependently ameliorated 3NP toxicity when applied simultaneously with the 3NP in Mg 21 -free media. Pretreatment of PCr for 2 or 5 days and Cr for 5 days protected against glutamate excitotoxicity equivalent to that achieved by MK801 post-treatment. The combination of PCr or Cr pretreatment and MK801 post-treatment did not provide additional protection, indicating that both prevented the toxicity attributable to secondary glutamate release. To determine if Cr or PCr directly inhibited the permeability transition, mitochondrial swelling and depolarization were assayed in isolated, puri®ed brain mitochondria. PCr reduced the amount of swelling induced by calcium by 20%. Cr decreased mitochondrial swelling when inhibitors of creatine kinase octamer±dimer transition were present. However, in brain mitochondria prepared from rats fed a diet supplemented with 2% creatine for 2 weeks, the extent of calcium-induced mitochondrial swelling was not altered. Thus, the neuroprotective properties of PCr and Cr may re¯ect enhancement of cytoplasmic high-energy phosphates but not permeability transition inhibition.

show abstract

Reduction of ventricular arrhythmias by phosphocreatine (Neoton) in patients with acute myocardial infarction

Cited by 43 publications

References 13 publications

Therapeutic Use of Creatine in Brain or Heart Ischemia: Available Data and Future Perspectives

Therapeutic Use of Creatine in Brain or Heart Ischemia: Available Data and Future Perspectives

Creatine: a miserable life without it

On the mechanisms of neuroprotection by creatine and phosphocreatine

Contact Info

Product

Resources

About